Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 1.00 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CCKAR | P32238 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371600 | 1.00 | CTSL (1.00) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL15232206 | 0.86 | CTSL (0.76) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL12371606 | 0.85 | CTSL (0.74) | CTSLCTSSCTSK | |
| SCHEMBL12370569 | 0.85 | CTSL (0.74) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL4214126 | 0.78 | CTSL (0.69) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL9542635 | 0.78 | CTSL (0.64) | CTSLCTSSCTSK | |
| SCHEMBL9544088 | 0.78 | CTSL (0.64) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL12371552 | 0.77 | CTSL (0.65) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL9543335 | 0.77 | CTSL (0.63) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL9543677 | 0.77 | CTSL (0.63) | CTSLCTSSCTSKMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873668-B2 | Compositions and methods for inhibition of cathepsins | MATEON THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160368869-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | BAYLOR UNIVERSITY | 2016-12-22 | — | — | US | disclosed |
| US-9458103-B2 | Compositions and methods for inhibition of cathepsins | MATEON THERAPEUTICS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150031915-A1 | Compositions and Methods for Inhibition of Cathepsins | MATEON THERAPEUTICS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8877967-B2 | Compositions and methods for inhibition of cathepsins | OXIGENE, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130296605-A1 | Compositions and Methods for Inhibition of Cathepsins | MATEON THERAPEUTICS, INC. | 2013-11-07 | — | — | US | disclosed |
| WO-2013142038-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | OXIGENE, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207726-A1 | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S | CTSB, CTSS, CTSV | CTSL 7/4885CTSS 2/4885CTSK 11/4885 |
| US-20150031915-A1 | Compositions and Methods for Inhibition of Cathepsins | CTSF, CTSS, CTSZ | CTSL 9/4885CTSS 2/4885CTSK 4/4885 |
| US-20130296605-A1 | Compositions and Methods for Inhibition of Cathepsins | CTSF, CTSS, CTSZ | CTSL 9/4885CTSS 2/4885CTSK 4/4885 |
| US-20160368869-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS | CTSF, CTSS, CTSZ | CTSL 9/4885CTSS 2/4885CTSK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.